Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
暂无分享,去创建一个
Brian A Ference | R. Giugliano | M. Sabatine | E. Braunwald | S. Grundy | S. Wiviott | M. Silverman | B. Ference | Scott M Grundy | Robert P Giugliano | Marc S Sabatine | Eugene Braunwald | Michael G. Silverman | Stephen D Wiviott | Michael G Silverman | Kyungah Im | K. Im
[1] Marc P. Bonaca,et al. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction , 2016, Circulation.
[2] Sidney C. Smith,et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2016, Journal of the American College of Cardiology.
[3] S. Yusuf,et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.
[4] S. Grundy. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia , 2016, Nature Reviews Cardiology.
[5] J. Mckenney,et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.
[6] Jennifer G. Robinson,et al. Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[7] M. Vrabel. Preferred Reporting Items for Systematic Reviews and Meta-Analyses. , 2015, Oncology nursing forum.
[8] R. Giugliano,et al. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? , 2015, Journal of the American College of Cardiology.
[9] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[10] R. Brook,et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.
[11] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[12] Jingwen Liu,et al. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. , 2014, Atherosclerosis.
[13] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[14] Diane Lacaille,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk , 2014 .
[15] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[16] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[17] Jennifer G. Robinson,et al. Reply: 2013 ACC/AHA guideline on the assessment of cardiovascular risk. , 2014, Journal of the American College of Cardiology.
[18] Abstr Act,et al. Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease , 2014 .
[19] A. Gotto,et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S] , 2013, Journal of Lipid Research.
[20] Jennifer G. Robinson,et al. Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.
[21] K. Williams,et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. , 2012, Journal of the American College of Cardiology.
[22] R. Collins,et al. Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.
[23] R. Collins,et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial , 2011 .
[24] S. Bonovas,et al. Efficacy and safety of more intensive lowering of LDL cholesterol , 2011, The Lancet.
[25] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.
[26] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[27] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.
[28] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[29] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[30] V. Fonseca,et al. Bile Acids and Metabolic Regulation , 2009, Diabetes Care.
[31] Jennifer G. Robinson,et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.
[32] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[33] A. Lichtenstein,et al. Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[34] 杏一 水野,et al. 5.Primary Prevention of Cardiovascular Disease with Pravastatin in Japan(MEGA Study) , 2008 .
[35] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[36] Yasuo Ohashi,et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.
[37] S. Pocock,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.
[38] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[39] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[40] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[41] Jennifer G. Robinson,et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. , 2005, Journal of the American College of Cardiology.
[42] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[43] U. Laufs,et al. Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[44] D. Hunninghake,et al. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.
[45] M. Pfeffer,et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes , 2004 .
[46] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[47] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[48] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[49] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[50] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[51] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[52] Guido Knapp,et al. Improved tests for a random effects meta‐regression with a single covariate , 2003, Statistics in medicine.
[53] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[54] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[55] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[56] M. Beylot,et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. , 2002, Diabetes.
[57] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[58] P. Serruys,et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention , 2002 .
[59] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[60] V. Athyros,et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.
[61] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[62] P. Renshaw,et al. [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.
[63] J. Farmer. Pleiotropic effects of statins , 2000, Current atherosclerosis reports.
[64] Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.
[65] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[66] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[67] A. Geyssant,et al. Effect of dietary cholesterol on low density lipoprotein-receptor, 3-hydroxy-3-methylglutaryl-CoA reductase, and low density lipoprotein receptor-related protein mRNA expression in healthy humans , 1998, Lipids.
[68] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[69] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[70] P. Kris-Etherton,et al. Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women. , 1997, Journal of lipid research.
[71] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.
[72] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[73] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[74] J P Matts,et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.
[75] Daniel Steinberg,et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.
[76] C. E. Becker. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.
[77] W. Martin,et al. Colestipol hydrochloride in hypercholesterolemic patients--effect on serum cholesterol and mortality. , 1978, Journal of chronic diseases.
[78] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.
[79] Paulleren. The Oslo Diet-Heart Study , 1970 .
[80] P. Leren. The Oslo Diet‐Heart Study: Eleven‐Year Report , 1970, Circulation.
[81] U. Tomiyasu,et al. A Controlled Clinical Trial of a Diet High in Unsaturated Fat in Preventing Complications of Atherosclerosis , 1969 .
[82] P. Allhoff,et al. Controlled trial of soya-bean oil in myocardial infarction. , 1968, Lancet.
[83] L. Michaels,et al. LOW-FAT DIET IN MYOCARDIAL INFARCTION , 1965 .